Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | PTGFR | P43088 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17684521 | 0.92 | PTGER4 (0.46) | PTGER4PTGDRPTGER2PTGER3TBXA2R | |
| SCHEMBL20113594 | 0.92 | PTGER4 (0.55) | PTGER4PTGDRPTGER2PTGER3TBXA2R | |
| SCHEMBL16305134 | 0.92 | PTGER4 (0.53) | PTGER4PTGDRPTGER2PTGER3TBXA2R | |
| SCHEMBL17740234 | 0.91 | PTGER4 (0.44) | PTGER4PTGDRPTGER2PTGER3TBXA2R | |
| SCHEMBL16305070 | 0.88 | PTGER4 (0.59) | PTGER4PTGDRPTGER2PTGER3TBXA2R | |
| SCHEMBL17684841 | 0.85 | PTGER4 (0.46) | PTGER4PTGDRPTGER2PTGER3TBXA2R | |
| SCHEMBL16305069 | 0.85 | PTGER4 (0.52) | PTGER4PTGER3 | |
| SCHEMBL17684663 | 0.83 | PTGER4 (0.36) | PTGER4PTGDRTBXA2R | |
| SCHEMBL16304052 | 0.82 | PTGER4 (0.42) | PTGER4PTGDRPTGER2PTGER3TBXA2R | |
| SCHEMBL16305067 | 0.82 | PTGER4 (0.62) | PTGER4PTGDRPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009426-B1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMA CO LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9593081-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3009426-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | Kaken Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | PTGER4 1/4885PTGDR 31/4885PTGER2 7/4885 |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | PTGER4 1/4885PTGDR 25/4885PTGER2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.